Shots:

• Merck KGaA to receive up front- additional regulatory- approval- and sales milestone along with royalties on sales of pimasertib and MSC2015103B. The agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of MEK inhibitors
• Day One plans to initiate a P-I/II study to evaluate the safety- tolerability- and preliminary efficacy of pimasertib in combination with DAY101 in patients aged ≥12yrs. with advanced solid tumors with MAPK inhibitors
• Pimasertib and MSC2015103B are oral- highly-selective MEK I/II inhibitors. Pimasertib has been studied in 10+ P-I/II studies in ~900 patients with various tumor types

 ­ Ref: Businesswire | Image: Merck KGaA